|
|
 |
|
Viewing report
|
|
|
|
Strategic Overview of the Infectious Disease Vaccine
Decision Resources, Inc, Aug 2011
Infectious disease (ID) vaccinations have significantly reduced mortality and morbidity in the Western hemisphere. However, despite the tremendous inroads made, significant unmet needs remain. The vast size of the potential patient population that could receive a new ID vaccine is one important reason that pharmaceutical companies are taking a fresh look at the vaccine sector. The ID vaccine pipeline is robust, a notable finding given the long length of time it takes to develop a vaccine and the many vaccines already available. Over 2005-2011, the worldwide market for vaccines against infectious diseases exhibited robust growth, with sales of innovative vaccines, such as Pfizer's Prevnar and Merck's Gardasil, contributing to this healthy increase. The development of new technologies, such as virus-like particles, recombinant vaccines, cellular expression systems, and DNA vaccines, is fueling the pharmaceutical industry's interest in the vaccine market and providing lucrative opportunities for companies with novel technologies and experimental candidates. Emerging markets, particularly the BRIC markets (Brazil, Russia, India, and China), promise to be new engines for pharma growth in the face of faltering growth rates and growing challenges in the traditional stronghold major markets. In this report, we provide a strategic overview of the ID vaccine sector, highlighting four key aspects of this marketplace: unmet needs and new opportunities, the ID vaccine pipeline, novel technologies and opportunities for next-generation vaccines, and pricing and reimbursement strategies for gaining access in emerging markets.
- Pharmaceutical manufacturers are taking a fresh look at the ID vaccines industry. What is the size of this market, and what is its growth trend? Which companies are the leaders based on 2010 sales? Will those rankings change? What opportunities are available to these and other contenders in the vaccines space?
- Vaccinations are in development for a wide array of infectious diseases, from those for which vaccines already exist to those for which no vaccines are on the market. Why is this variety of vaccines needed? Which diseases are receiving the most attention from developers?
- Physicians (ID specialists, PCPs, and pediatricians) surveyed by Decision Resources have diverse opinions regarding the unmet needs of the ID vaccine pipeline. What are the diseases with the greatest unmet need in terms of vaccines, according to each physician specialty? Is there any consensus among the specialties regarding unmet needs?
- Many infectious diseases lack effective prophylactic vaccines, and the industry faces a variety of challenges in vaccine design and production. What novel technologies hold the most promise for vaccine development? Which new treatment strategies are being pursued, and which are the most advanced?
- Adjuvants and delivery methods are key technologies for the success of future vaccines. What types of novel adjuvants and delivery methods are under investigation? What companies are leading the development of these programs?
- Emerging markets offer to the international pharmaceutical industry opportunities that are increasingly dwindling in the mature markets. How have funding and structural reforms changed the landscape of healthcare access and expenditures in emerging markets? What aspects of emerging markets' economies, demographics, and healthcare systems are favorable for vaccine marketers? Who are the major purchasers of vaccines in BRIC countries?
- Just a handful of MNCs dominated the global vaccine market in 2010. What strategies have leading MNCs used to gain access to emerging markets? How important are emerging-market sales to MNCs' current vaccine businesses? Will GlaxoSmithKline, Sanofi, Pfizer, and Merck retain their market-leading positions through 2017?
Scope
Introduction to the vaccine market: Market size, market growth, market drivers, product sales, unmet needs.
Primary research: Results from a February 2011 Web-based survey of 106 U.S. physicians who administer ID vaccines: ID specialists, pediatricians, and primary care physicians (PCPs).
Markets covered: United States, BRIC markets, South Korea, Turkey, rest of world (ROW).
Salient events and trends: HIV vaccine development, prime-boost approach, RV-144, broadly active neutralizing antibodies, therapeutic versus prophylactic HIV vaccines, HPV vaccinations, adolescent immunization schedules, vaccine safety, vaccine/autism link.
Unmet needs: By segment, age-group, pathogen, and need in the clinical setting.
Vaccine pipeline: Agents, companies, unmet needs, emerging markets.
Vaccine technologies: Current technologies, cell-based methods, innovative technologies, adjuvant technologies, emerging alternative delivery systems.
Company profiles: GlaxoSmithKline, Sanofi, Merck & Co., DynaVax Technologies, Inovio Pharmaceuticals, Protein Sciences, Novavax, VaxInnate, Vical, others.
Deals: Select mergers, acquisitions, and partnerships and how they demonstrate opportunity and strategy.
Emerging markets: BRIC healthcare system overviews, company strategies, vaccine development, companies, market trends.
Market forecast and outlook: Worldwide and U.S. market size over 2005-2017; key competitors and their market share; market drivers and constraints, market expansion, emerging markets, partnering and M&A, government and nonprofit involvement, safety challenges.
Data-rich content: 98 data-rich tables and figures showing market data, analysis, and survey results.
|
|
|
|
